The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Halozyme
Stock and Other Ownership Interests - Halozyme
Time and Dose-Intense Neoadjuvant Therapy for Locally Advanced Breast Carcinoma.
 
Mitesh J. Borad
Stock and Other Ownership Interests - Gilead Sciences; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); TD2
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun BioPharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Rachna T. Shroff
Consulting or Advisory Role - Agios; Amgen; Celgene; Codiak Biosciences; Halozyme
Research Funding - Agios; Celgene; Lilly
Travel, Accommodations, Expenses - Agios; Amgen; Celgene; Codiak Biosciences; Halozyme
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Agios; Array BioPharma (I); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boston Scientific; Bristol-Myers Squibb (I); CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; Delcath Systems; Eisai; EMD Serono (I); Gilead Sciences (I); Halozyme (I); IntegraGen; Ipsen; Janssen (I); Medimmune; Merck Serono; Merrimack; Merrimack (I); Momenta Pharmaceuticals (I); New B Innovation; Newlink Genetics (I); Onxeo; Opsona Therapeutics (I); Pfizer (I); Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; VAXIMM (I); Vicus Therapeutics; Vicus Therapeutics (I); Westhaven
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Chugai Pharma (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris
 
J. Randolph Hecht
Consulting or Advisory Role - Actym Therapeutics; Amgen; ARMO BioSciences; Astellas Pharma; Bristol-Myers Squibb; Forty Seven; Genentech/Roche; Halozyme; Rafael Pharmaceuticals; Viralytics
Research Funding - Advaxis (Inst); Amgen (Inst); ARMO BioSciences (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Halozyme (Inst)
 
Andrea J. Bullock
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Medtronic
Consulting or Advisory Role - Bayer; Celgene; Halozyme
 
Paul S. Ritch
No Relationships to Disclose
 
Dimitrios Chondros
No Relationships to Disclose
 
Mann Muhsin
Employment - Halozyme
Stock and Other Ownership Interests - Halozyme
 
Do-Youn Oh
Consulting or Advisory Role - Lilly; MSD; Roche
Research Funding - AstraZeneca